KZIAKAZIA THERAPEUTICS LTD

Nasdaq kaziatherapeutics.com


$ 0.22 $ -0.01 (-5.16 %)    

Monday, 01-Jul-2024 15:59:50 EDT
QQQ $ 486.13 $ 6.23 (1.3 %)
DIA $ 392.99 $ 2.15 (0.55 %)
SPY $ 548.10 $ 4.36 (0.8 %)
TLT $ 90.61 $ -0.06 (-0.07 %)
GLD $ 215.55 $ 0.28 (0.13 %)
$ 0.2168
$ 0.22
$ 0.00 x 0
$ 0.00 x 0
$ 0.22 - $ 0.22
$ 0.19 - $ 1.28
146,955
na
4.94M
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2006 11-06-2006 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 kazia-to-present-dipg-data-at-ispno-june-29---july-2

Kazia Therapeutics Limited (NASDAQ:KZIA), a biotechnology company specialising in oncology, is pleased to announce the presenta...

 kazia-therapeutics-says-nasdaq-determined-that-company-is-eligible-for-additional-180-calendar-day-period-or-until-november-18-2024-to-regain-compliance

On May 22, 2024, the Company received a letter from Nasdaq notifying the Company that, while the Company has not regained compl...

 kazia-therapeutics-ltd-entered-into-purchase-agreement-with-alumni-capital-lp-pursuant-to-purchase-agreement-may-sell-to-alumni-capital-up-to-15m-of-american-depositary-shares-from-time-to-time

- SEC Filing

 why-nextplat-shares-are-trading-higher-by-around-30-here-are-20-stocks-moving-premarket

Shares of NextPlat Corp (NASDAQ: NXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023...

 why-byrna-technologies-shares-are-trading-higher-by-around-7-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-ex...

 whats-going-with-australia-based-cancer-firm-kazia-therapeutics-on-wednesday

Kazia Therapeutics' Phase 1 trial of paxalisib with radiation therapy in solid tumors, demonstrates safety, clinical activi...